Imipenem/Cilastatin/Relebactam PK in ECMO

计划入组 8 人 · 首次发布于 2020 年 7 月 30 日

Imipenem/Cilastatin-XNW4107 Versus Imipenem/Cilastatin/Relebactam for Treatment of Participants With Bacterial Pneumonia (XNW4107-302, REITAB-2)

计划入组 450 人 · 首次发布于 2022 年 1 月 24 日

Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium+Imipenem+Cilastatin in Imipenem-Resistant Bacterial Infection (MK-7655A-013)

计划入组 50 人 · 首次发布于 2015 年 5 月 22 日

Imipenem-Cilastatin

Rx

imipenem + cilastatin sodium + funobactam

Imipenem(Primaxin, Recarbrio)

C₁₂H₁₇N₃O₄S

Spero Therapeutics Initiates Phase 3 Trial for First Oral Carbapenem in US, Targeting Complicated UTIs

FDA Approves Merck's Recarbrio for Complex Infections with Antimicrobial Stewardship Focus

Spero Therapeutics' Tebipenem HBr Phase 3 Trial Enrollment Nears Completion